BIOKID: Randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991]
<p>Abstract</p> <p>Background</p> <p>Peritoneal dialysis (PD) is the preferred dialysis modality in children. Its major drawback is the limited technique survival due to infections and progressive ultrafiltration failure. Conventional PD solutions exert marked acute and...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2004-10-01
|
| Series: | BMC Nephrology |
| Online Access: | http://www.biomedcentral.com/1471-2369/5/14 |
| _version_ | 1819034152235696128 |
|---|---|
| author | Misselwitz Joachim Haluany Karin Fischbach Michel Edefonti Alberto Bonzel Klaus E Ardissino Gianluigi Arbeiter Klaus Almeida Margarida Schmitt Claus P Nau Barbara Kemper Markus J Rönnholm Kai Wygoda Simone Schaefer Franz |
| author_facet | Misselwitz Joachim Haluany Karin Fischbach Michel Edefonti Alberto Bonzel Klaus E Ardissino Gianluigi Arbeiter Klaus Almeida Margarida Schmitt Claus P Nau Barbara Kemper Markus J Rönnholm Kai Wygoda Simone Schaefer Franz |
| author_sort | Misselwitz Joachim |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Peritoneal dialysis (PD) is the preferred dialysis modality in children. Its major drawback is the limited technique survival due to infections and progressive ultrafiltration failure. Conventional PD solutions exert marked acute and chronic toxicity to local tissues. Prolonged exposure is associated with severe histopathological alterations including vasculopathy, neoangiogenesis, submesothelial fibrosis and a gradual loss of the mesothelial cell layer. Recently, more biocompatible PD solutions containing reduced amounts of toxic glucose degradation products (GDPs) and buffered at neutral pH have been introduced into clinical practice. These solutions contain lactate, bicarbonate or a combination of both as buffer substance. Increasing evidence from clinical trials in adults and children suggests that the new PD fluids may allow for better long-term preservation of peritoneal morphology and function. However, the relative importance of the buffer in neutral-pH, low-GDP fluids is still unclear. In vitro, lactate is cytotoxic and vasoactive at the concentrations used in PD fluids. The BIOKID trial is designed to clarify the clinical significance of the buffer choice in biocompatible PD fluids.</p> <p>Methods/design</p> <p>The objective of the study is to test the hypothesis that bicarbonate based PD solutions may allow for a better preservation of peritoneal transport characteristics in children than solutions containing lactate buffer. Secondary objectives are to assess any impact of the buffer system on acid-base status, peritoneal tissue integrity and the incidence and severity of peritonitis.</p> <p>After a run-in period of 2 months during which a targeted cohort of 60 patients is treated with a conventional, lactate buffered, acidic, GDP containing PD fluid, patients will be stratified according to residual renal function and type of phosphate binding medication and randomized to receive either the lactate-containing Balance<sup/> solution or the bicarbonate-buffered Bicavera<sup>® </sup>solution for a period of 10 months. Patients will be monitored by monthly physical and laboratory examinations. Peritoneal equilibration tests, 24-h dialysate and urine collections will be performed 4 times. Peritoneal biopsies will be obtained on occasion of intraabdominal surgery. Changes in small solute transport rates, markers of peritoneal tissue turnover in the effluent, acid-base status and peritonitis rates and severity will be analyzed.</p> |
| first_indexed | 2024-12-21T07:29:11Z |
| format | Article |
| id | doaj.art-c70e6afec6dc44e99886fec2e29ad585 |
| institution | Directory Open Access Journal |
| issn | 1471-2369 |
| language | English |
| last_indexed | 2024-12-21T07:29:11Z |
| publishDate | 2004-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj.art-c70e6afec6dc44e99886fec2e29ad5852022-12-21T19:11:37ZengBMCBMC Nephrology1471-23692004-10-01511410.1186/1471-2369-5-14BIOKID: Randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991]Misselwitz JoachimHaluany KarinFischbach MichelEdefonti AlbertoBonzel Klaus EArdissino GianluigiArbeiter KlausAlmeida MargaridaSchmitt Claus PNau BarbaraKemper Markus JRönnholm KaiWygoda SimoneSchaefer Franz<p>Abstract</p> <p>Background</p> <p>Peritoneal dialysis (PD) is the preferred dialysis modality in children. Its major drawback is the limited technique survival due to infections and progressive ultrafiltration failure. Conventional PD solutions exert marked acute and chronic toxicity to local tissues. Prolonged exposure is associated with severe histopathological alterations including vasculopathy, neoangiogenesis, submesothelial fibrosis and a gradual loss of the mesothelial cell layer. Recently, more biocompatible PD solutions containing reduced amounts of toxic glucose degradation products (GDPs) and buffered at neutral pH have been introduced into clinical practice. These solutions contain lactate, bicarbonate or a combination of both as buffer substance. Increasing evidence from clinical trials in adults and children suggests that the new PD fluids may allow for better long-term preservation of peritoneal morphology and function. However, the relative importance of the buffer in neutral-pH, low-GDP fluids is still unclear. In vitro, lactate is cytotoxic and vasoactive at the concentrations used in PD fluids. The BIOKID trial is designed to clarify the clinical significance of the buffer choice in biocompatible PD fluids.</p> <p>Methods/design</p> <p>The objective of the study is to test the hypothesis that bicarbonate based PD solutions may allow for a better preservation of peritoneal transport characteristics in children than solutions containing lactate buffer. Secondary objectives are to assess any impact of the buffer system on acid-base status, peritoneal tissue integrity and the incidence and severity of peritonitis.</p> <p>After a run-in period of 2 months during which a targeted cohort of 60 patients is treated with a conventional, lactate buffered, acidic, GDP containing PD fluid, patients will be stratified according to residual renal function and type of phosphate binding medication and randomized to receive either the lactate-containing Balance<sup/> solution or the bicarbonate-buffered Bicavera<sup>® </sup>solution for a period of 10 months. Patients will be monitored by monthly physical and laboratory examinations. Peritoneal equilibration tests, 24-h dialysate and urine collections will be performed 4 times. Peritoneal biopsies will be obtained on occasion of intraabdominal surgery. Changes in small solute transport rates, markers of peritoneal tissue turnover in the effluent, acid-base status and peritonitis rates and severity will be analyzed.</p>http://www.biomedcentral.com/1471-2369/5/14 |
| spellingShingle | Misselwitz Joachim Haluany Karin Fischbach Michel Edefonti Alberto Bonzel Klaus E Ardissino Gianluigi Arbeiter Klaus Almeida Margarida Schmitt Claus P Nau Barbara Kemper Markus J Rönnholm Kai Wygoda Simone Schaefer Franz BIOKID: Randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991] BMC Nephrology |
| title | BIOKID: Randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991] |
| title_full | BIOKID: Randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991] |
| title_fullStr | BIOKID: Randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991] |
| title_full_unstemmed | BIOKID: Randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991] |
| title_short | BIOKID: Randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991] |
| title_sort | biokid randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children isrctn81137991 |
| url | http://www.biomedcentral.com/1471-2369/5/14 |
| work_keys_str_mv | AT misselwitzjoachim biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT haluanykarin biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT fischbachmichel biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT edefontialberto biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT bonzelklause biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT ardissinogianluigi biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT arbeiterklaus biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT almeidamargarida biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT schmittclausp biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT naubarbara biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT kempermarkusj biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT ronnholmkai biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT wygodasimone biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 AT schaeferfranz biokidrandomizedcontrolledtrialcomparingbicarbonateandlactatebufferinbiocompatibleperitonealdialysissolutionsinchildrenisrctn81137991 |